AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1895262
Drug: Cyclosporine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (initial daily dose 5 mg/kg)
Trial: 1895262
Drug: D-penicillamine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine (initial daily dose 250 mg)
Trial: 31729326
Drug: Immediate blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate blood transfusion (higher volume: 30 mL/kg whole blood / 15 mL/kg packed cells; lower volume: 20 mL/kg whole blood / 10 mL/kg packed cells)
Trial: 31729326
Drug: Immediate blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate blood transfusion (20 mL/kg whole blood equivalent)
Trial: 28323798
Drug: FiO2 80%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FiO2 80% (Supplemental perioperative oxygen therapy)
Trial: 26515269
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin (0.5 mg/kg)
Trial: 24486687
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.2% Glyceryl Trinitrate and 2% lignocaine ointment (Group A)
Trial: 24486687
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine ointment (Group B)
Trial: 24486687
Drug: 0.2% Glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% Glyceryl Trinitrate ointment (Group C)
Trial: 17244902
Drug: Repetitive low-energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive low-energy shock-wave therapy (SWT)
Trial: 15978302
Drug: Ipratropium/albuterol 36/206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium/albuterol 36/206 microg QID (IB/ALB)
Trial: 12785670
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period of traditional treatment
Trial: 10234599
Drug: Ganciclovir 1000
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir 1000 mg q8h with zalcitabine 0.75 mg q8h
Trial: 10234599
Drug: Ganciclovir 1000
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir 1000 mg q8h with stavudine 40 mg q12h
Trial: 10234599
Drug: Ganciclovir 1000
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir 1000 mg q8h alone
Trial: 8598547
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg vitamin A (retinyl palmitate)
Trial: 1959720
Drug: Inhaled fenoterol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fenoterol, 0.2 mg 4 times daily for 7 days
Trial: 19281636
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 40 mg/kg praziquantel with 2 weeks interval
Trial: 19281636
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 40 mg/kg praziquantel
Trial: 10636605
Drug: Psychosocially enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocially enhanced treatment program (PET)
Trial: 10636605
Drug: Case management-oriented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case management-oriented outpatient treatment program (CM)
Trial: 21806904
Drug: Parental presence
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental presence during dental treatment
Trial: 8417772
Drug: Parental absence
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental absence during dental treatment
Trial: 3804028
Drug: Cimetidine plus
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine plus sulpiride 200 mg daily
Trial: 29356277
Drug: New complex
RxNorm normalized name: TITANIUM DIOXIDE 4 mg in 1 mL TOPICAL PASTE [Revlon New Complexion One-Step Perfect Make-Up]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New complex cream composed of Yunnan Portulaca oleracea extract, Prinsepia utilis oil, beta‐glucan, and sodium hyaluronate, applied twice daily for 28 days.
Trial: 29356277
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream (tolerance‐extreme cream), applied twice daily for 28 days.
Trial: 29356277
Drug: New complex
RxNorm normalized name: TITANIUM DIOXIDE 4 mg in 1 mL TOPICAL PASTE [Revlon New Complexion One-Step Perfect Make-Up]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New complex cream
Trial: 29231520
Drug: Quick needle
RxNorm normalized name: Cal-Quick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quick needle insertion therapy at Aqiang point
Trial: 24758164
Drug: Individualised audit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised audit and feedback (A&F) strategies for antibiotic prescribing
Trial: 17058829
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy (DFIPRS) in addition to anti-asthmatic medicine
Trial: 17058829
Drug: Anti-asthmatic medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-asthmatic medicine only (control group)
Trial: 10834678
Drug: Dopamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine at a renal dose (2.5 microg/kg/min)
Trial: 10834678
Drug: Dopamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine at higher doses (10 microg/kg/min)
Trial: 8800254
Drug: Veterinarians enrolled
RxNorm normalized name: Enromed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veterinarians enrolled in a dairy production medicine continuing education program (treatment herds)
Trial: 1364078
Drug: Clozapine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (500 mg/day)
Trial: 1364078
Drug: Chlorpromazine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (600 mg/day)
Trial: 6370976
Drug: Nomifensine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine (150 mg/day)
Trial: 25022939
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patches (maximum maintenance dose of 16 mg/24 h)
Trial: 25022939
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patches
Trial: 20009770
Drug: SPIRO 50
RxNorm normalized name: 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPIRO 50 mg once daily for 12 weeks
Trial: 20009770
Drug: BFZ 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFZ 2.5 mg once daily for 12 weeks
Trial: 20009770
Drug: SPIRO 50
RxNorm normalized name: 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPIRO 50 mg
Trial: 20009770
Drug: BFZ 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFZ 2.5 mg
Trial: 15926441
Drug: Computerized injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized injection device
Trial: 10351924
Drug: Zafirlukast (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast (20 mg twice a day)
Trial: 10351924
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (200 microg twice a day)
Trial: 7496001
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination of 50 mg isoniazid + 120 mg rifampicin + 300 mg pyrazinamide
Trial: 7496001
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of the 3 antituberculosis drugs
Trial: 7496001
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (triple combination and separate drugs)
Trial: 7006544
Drug: 1 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL/kg of 50% dextrose in water (D50W)
Trial: 31726963
Drug: Clopidogrel-Aspirin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-Aspirin therapy
Trial: 29047413
Drug: VHA-guided transfusion
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VHA-guided transfusion therapy
Trial: 29047413
Drug: CCT-guided transfusion
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCT-guided transfusion therapy
Trial: 29047413
Drug: CCT-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCT-guided therapy
Trial: 29047413
Drug: VHA-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VHA-guided therapy
Trial: 21646441
Drug: Pregabalin add-on
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin add-on therapy
Trial: 17536120
Drug: EGCG (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (300 mg)
Trial: 17536120
Drug: EGCG (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (150 mg twice daily for two weeks)
Trial: 17536120
Drug: EGCG (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (acute treatment)
Trial: 17536120
Drug: EGCG (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (two weeks treatment)
Trial: 15467101
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Cr-pic
Trial: 11426898
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg and 50 mg
Trial: 11120458
Drug: Enalapril (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (0.25 mg/kg/day)
Trial: 9105164
Drug: C II
RxNorm normalized name: Xedec II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C II treatment (chicken cartilage soup containing heat degenerated C II)
Trial: 2951824
Drug: Ipratropium bromide,
RxNorm normalized name: Ipratropium Bromide, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide, 0.5 mg + fenoterol, 2.0 mg
Trial: 27018896
Drug: Local administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local administration of depomedrol
Trial: 20201624
Drug: Internet-based coaching,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based coaching, daily use of proprietary olfactive-based personal care products, and periodic feedback reports (Group 1)
Trial: 10080400
Drug: Polyclonal antibody
RxNorm normalized name: Polyclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyclonal antibody ATG for DGF
Trial: 8530600
Drug: Sublingual testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual testosterone cyclodextrin (SLT; 2.5 mg, administered three times per day)
Trial: 8530600
Drug: Sublingual testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual testosterone cyclodextrin (SLT; 5.0 mg, administered three times per day)
Trial: 8530600
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE; 200 mg, given once every 20 days by IM injections)
Trial: 28806532
Drug: Oral phosphate
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral phosphate load (PHOS; liquid supplement containing 1200 mg of phosphorus)
Trial: 28806532
Drug: Oral phosphate
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral phosphate load (PHOS)
Trial: 24494282
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy at specific points (Yaoyangguan, Mingmen, Zhiyang, Shenzhu, Dazhui, Yamen, Fengfu, Baihui, Neck‐Jiaji) given 6 times a week for 21 days.
Trial: 21717781
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (Ashi‐point, Baihui (GV 20), Taiyang (EX‐HN 5), Shuaigu (GB 8), Fengchi (GB 20), Benshen (GB 13), Lieque (LU 7), needles retained for 30 min, once daily, 6 times a week for 4 weeks)
Trial: 21717781
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment (Flunarizine 10 mg, once every night for 4 weeks)
Trial: 11810777
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (oral tamoxifen for five years; premenopausal patients received bilateral ovary ablation followed by tamoxifen for five years)
Trial: 11810777
Drug: Chemotherapy (CTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CTX + MTX + 5‐Fu + VCR + DXM (CMFVP) or CTX + MTX + 5‐Fu (CMF))
Trial: 9569476
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine combined with diphtheria and tetanus toxoids (PRP-T)
Trial: 2567739
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 12 mg acrivastine
Trial: 2567739
Drug: Colonic administration
RxNorm normalized name: colonial bent grass pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colonic administration of 12 mg acrivastine
Trial: 1099491
Drug: AN448 (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN448 (active drug)
Trial: 30904834
Drug: Dexamethasone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.2 mg/kg at the end of the surgical procedure and at day +1, n=611)
Trial: 10511768
Drug: Furosemide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (1 mg/kg)
Trial: 16937132
Drug: Sonic tooth
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonic tooth brushing and oral hygiene instruction
Trial: 9330783
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate metered-dose inhaler (CFC-free) at 50 micrograms/actuation
Trial: 9330783
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate metered-dose inhaler (CFC-free) at 100 micrograms/actuation
Trial: 9330783
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate metered-dose inhaler (CFC-free) at 200 micrograms/actuation
Trial: 8222650
Drug: 20 mcg
RxNorm normalized name: Caverject 20 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mcg ethinyl-estradiol (MERCILON)
Trial: 8222650
Drug: 30 mcg
RxNorm normalized name: Avonex 30 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mcg ethinyl-estradiol (MARVELON)
Trial: 30919948
Drug: Intrathecal (IT)
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal (IT) opioid administration with hydromorphone
Trial: 28474741
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Daclatasvir
Trial: 25159700
Drug: MoodCare (telephone-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MoodCare (telephone-delivered cognitive behavioural therapy and risk-reduction programme)
Trial: 3297265
Drug: Propafenone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (150 mg quid)
Trial: 31724253
Drug: US reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US reference insulin glargine (US IG)
Trial: 31724253
Drug: European reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: European reference insulin glargine (EU IG)
Trial: 30453494
Drug: Pistacia lentiscus
RxNorm normalized name: Pistacia Lentiscus Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistacia lentiscus (PL) supplement (2.8 g/day) for 3 months
Trial: 30453494
Drug: Pistacia lentiscus
RxNorm normalized name: Pistacia Lentiscus Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistacia lentiscus (PL) supplement
Trial: 16182832
Drug: corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corticosteroid therapy (control group)
Trial: 11509496
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (20 g/day for 5 days followed by 5 g/day for 3-4 days)
Trial: 9506757
Drug: Intravenous cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cocaine (0.2 mg/kg)
Trial: 7522315
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (0.1% fluorometholone for 6 months)
Trial: 7522315
Drug: Plasmin inhibitors
RxNorm normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmin inhibitors (aprotinin 40 IU/ml for 3 weeks)
Trial: 7522315
Drug: Plasmin inhibitors
RxNorm normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmin inhibitors (aprotinin)
Trial: 3351000
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate 12.5 mg intramuscularly every 2 weeks
Trial: 21839757
Drug: Theobromine (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theobromine (700 mg)
Trial: 21839757
Drug: Caffeine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (120 mg)
Trial: 21839757
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of caffeine and theobromine
Trial: 15577539
Drug: Emtricitabine 200
RxNorm normalized name: emtricitabine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine 200 mg QD
Trial: 12407485
Drug: Lamivudine 150
RxNorm normalized name: lamivudine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 150 mg BID
Trial: 11354919
Drug: Topical penciclovir
RxNorm normalized name: penciclovir Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical penciclovir applied every 2 hours during waking hours
Trial: 11354919
Drug: Topical acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acyclovir applied every 2 hours during waking hours
Trial: 8173850
Drug: TENS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS plus placebo drug
Trial: 7487614
Drug: No systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systemic antibiotics
Trial: 31565730
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for fit patients
Trial: 24660605
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus Xuebijing (XBJ) injection
Trial: 15483085
Drug: Mifepristone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (40 mg daily)
Trial: 15483085
Drug: Mifepristone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (40 mg daily) + hCG
Trial: 15483085
Drug: Mifepristone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (40 mg daily) without hCG (P only)
Trial: 15483085
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (GnRH agonists)
Trial: 30535537
Drug: Octreotide SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide SC depot 10 mg q2w
Trial: 30535537
Drug: Octreotide SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide SC depot 20 mg q4w
Trial: 23261122
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (scaling and root planing, extraction of hopeless teeth, local-delivery antibiotics)
Trial: 23261122
Drug: Control (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (treatment after 6 months)